Clinical trials: Cervical Intraepithelial Neoplasia Grade 2/3
Human Papillomavirus Associated Intraepithelial Neoplasia, Cervical Intraepithelial Neoplasia Grade 2/3
A Study in Subjects With Human Papillomavirus 16 or 18 Associated Cervical Intraepithelial Neoplasia Grade 2 or 3
The purpose of this study is to to evaluate the safety, tolerability, immunogenicity, and efficacy of RG002 Injection in subjects with HPV16/18 associated Cervical Intraepithelial Neoplasia Grade 2 or 3(CIN2/3).
- Conditions
- Human Papillomavirus Associated Intraepithelial Neoplasia, Cervical Intraepithelial Neoplasia Grade 2/3, Human Papillomavirus Type 16 Infection, Human Papillomavirus Type 18 Infection
- Trial name
- NCT06273553
- Testing
- RG002 injection
- Volunteers
- 39 people
- Sponsor
- RinuaGene Biotechnology Co., Ltd.
Cervical Intraepithelial Neoplasia Grade 2/3
Efficacy and Safety of Cevira® in Patients With Cervical Histologic High-grade Squamous Intraepithelial Lesions (HSIL)
A double blind, prospective, randomized, placebo controlled, multi-center phase 3 study to evaluate efficacy and safety of Cevira® in patients with cervical histologic high-grade squamous intraepithelial lesions (HSIL).
- Trial name
- APRICITY (NCT04484415)
- Testing
- Cevira®
- Where
- China
- Volunteers
- 402 people
- Sponsor
- Asieris MediTech (Hong Kong) Co., Ltd.
Cervical Cancer, Precancerous Condition
Diindolylmethane in Treating Patients With Abnormal Cervical Cells
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming. The use of diindolylmethane, a substance found in cruciferous vegetables, may keep cervical intraepithelial neoplasia or cervical cancer from…
- Trial name
- NCT00462813
- Testing
- oral microencapsulated diindolylmethane, polymerase chain reaction, cervical Papanicolaou test
- Where
- 2 sites in United Kingdom
- Volunteers
- 3,000 people
- Sponsor
- Barts and the London School of Medicine and Dentistry
Cervical Cancer, Precancerous Condition
Gene Expression Profiling of Cervical Cancer Progression in Biopsies and Tissue Samples
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- SAGE (NCT00629577)
- Testing
- microarray analysis, flow cytometry, biopsy
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- British Columbia Cancer Agency
CIN 2/3
Safety and Efficacy of Oral Artesunate for Pre-cervical Cancer
NeoART-CIN is a Phase II clinical study evaluating the safety and effectiveness of oral artesunate in patients with pre-cancerous cervical intra-epithelial neoplasia (CIN2/3), to investigate if a course of treatment with oral…
- Trial name
- NeoART-CIN (NCT07095478)
- Testing
- Artesunate
- Where
- 5 sites in Malaysia
- Volunteers
- 28 people
- Sponsor
- Metanoic Health Ltd.
Human Papillomavirus, CIN 2
Natural History of HPV From Infection to Neoplasia in Adolescents and Young Women
The natural history of human papillomavirus (HPV) is most likely influenced by both innate and adaptive mucosal immunity. More specifically, we hypothesize that Toll like receptors (TLR) play an important role in cervical innate…
- Conditions
- Human Papillomavirus, CIN 2, CIN 3
- Trial name
- NCT01366742
- Where
- 2 sites in United States
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Cervical Intraepithelial Neoplasia Grade 2/3, High-risk HPV (Any Strain)
Intravaginal Artesunate for the Treatment of HPV+ High Grade Cervical Intraepithelial Neoplasia (CIN2/3)
This phase I research protocol is designed to assess immunogenicity and clinical endpoints in patients with human papillomavirus (HPV) 16 cervical intraepithelial neoplasia (CIN)2/3.
- Trial name
- NCT02354534
- Testing
- Artesunate Suppositories
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Cervical Intraepithelial Neoplasia, Uterine Cervical Dysplasia
A Two-Stage Phase 2 Study Of A-007 Topical Gel in High-Grade Squamous Intraepithelial Lesions (HSIL)
A-007 is an investigational therapy which may be effective in the treatment of pre-cancerous cervical dysplasia (abnormal cell growth).
- Trial name
- TG-003 (NCT00596258)
- Testing
- A-007
- Where
- 5 sites in United States
- Volunteers
- 11 people
- Sponsor
- Tigris Pharmaceuticals
Cervical High Grade Squamous Intraepithelial Lesion, Cervical Intraepithelial Neoplasia Grade 2/3
Predicting Response In Cervical Intraepithelial Neoplasia to Topical Imiquimod Treatment
Imiquimod is a good non-invasive treatment option for women with cervical high-grade squamous intraepithelial neoplasia (cHSIL), especially those with a possible (future) pregnancy wish.
- Conditions
- Cervical High Grade Squamous Intraepithelial Lesion, Cervical Intraepithelial Neoplasia Grade 2/3, CIN 2/3, Cervical Intraepithelial Neoplasia
- Trial name
- PRedICT-TOPIC (NCT05405270)
- Testing
- Imiquimod, 3x vaginal swab for microbiome analysis, Expectative management
- Where
- 15 sites in Netherlands
- Volunteers
- 410 people
- Sponsor
- Catharina Ziekenhuis Eindhoven
Cervical Intraepithelial Neoplasia
Cryotherapy vs. LEEP to Treat Cervical Intraepithelial Neoplasia (CIN) 2/3 Among HIV-positive Women
The purpose of this study is to compare the rate of recurrence of cervical intraepithelial neoplasia among HIV-positive women receiving cryotherapy versus LEEP over 2 years of follow-up and to compare the shedding of HIV-1 from…
- Trial name
- PHE-LEEP (NCT01298596)
- Testing
- Loop Electrosurgical Excision Procedure (LEEP), Cryotherapy
- Where
- Kenya
- Volunteers
- 400 people
- Sponsor
- University of Washington
Cervical Cancer, Precancerous Condition
Fenretinide in Treating Patients With Cervical Neoplasia
RATIONALE: Chemoprevention uses drugs to try and prevent development of cancer. Fenretinide may be effective in treating cervical neoplasia and preventing cervical cancer.
- Trial name
- NCT00003075
- Testing
- Fenretinide
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- M.D. Anderson Cancer Center
Cervical Cancer, Precancerous Condition
Folic Acid Clinical Trial for the Prevention of Cervical Cancer
RATIONALE: Supplements, such as folic acid, may stop or delay the development of cervical cancer in women infected with human papillomavirus.
- Trial name
- NCT00703196
- Testing
- folic acid
- Where
- United States
- Volunteers
- 368 people
- Sponsor
- University of Alabama at Birmingham
Cervical Intraepithelial Neoplasia
Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Plasmid DNA Therapeutic Vaccine(GX-188E)
The purpose of this study is to access the efficacy and safety of GX-188E according the protocol in patients with Cervical Intraepithelial Neoplasia 2, 2/3 or 3 (CIN3)
- Trial name
- NCT02596243
- Testing
- GX-188E
- Where
- 16 sites in Estonia, South Korea and 1 more
- Volunteers
- 134 people
- Sponsor
- Genexine, Inc.
Human Papillomavirus (HPV)
Fourth Dose of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + EP in Adult Females Previously Vaccinated With Three Doses of VGX-3100
DNA vaccines, which are small pieces of DNA also known as plasmids, have several advantages over traditional vaccines such as live attenuated virus and recombinant protein-based vaccines.
- Trial name
- NCT01188850
- Testing
- VGX-3100
- Where
- 3 sites in United States, Puerto Rico
- Volunteers
- 14 people
- Sponsor
- Inovio Pharmaceuticals
Cervical Cancer, Vulvar Cancer
Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
The study will evaluate the immunogenicity and safety of 4-valent and 9-valent HPV recombinant vaccine in Chinese healthy females 20 to 45 years of age.
- Conditions
- Cervical Cancer, Vulvar Cancer, Vaginal Cancer, CIN1
- Trial name
- NCT04425291
- Testing
- 4-valent HPV Vaccine, 9-valent HPV Vaccine, GARDASIL®
- Where
- China
- Volunteers
- 1,680 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
Precancerous Condition, Cervical Cancer
Pilot Study In Vivo Confocal Microscopy Probe for Cervical Precancer
The goal of this proposal is to determine whether a hand-held confocal microscopy probe may perform better than standard methods in detecting cancer or pre-cancerous abnormalities of the cervix.
- Trial name
- Confocal (NCT02574442)
- Testing
- In Vivo Confocal Microscopy Probe
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- British Columbia Cancer Agency
Magnetic Resonance Imaging Examination
Clinical Value of the MRI Combined With SCC-Ag for the Diagnosis of HSIL (CIN 2/3)
The study aimed to identify the clinical value of Magnetic Resonance Imaging examination (MRI)combined with serum squamous cells carcinoma antigen (SCC-Ag) in women with high-grade squamous intraepithelial lesion (cervical…
- Trial name
- NCT05487209
- Testing
- MRI,SCC-Ag
- Where
- China
- Volunteers
- 186 people
- Sponsor
- Second Affiliated Hospital of Wenzhou Medical University
Cervical Dysplasia
A Phase II Single-arm Intervention Trial of Nelfinavir in Patients With Grade 2/3 or 3 Cervical Intraepithelial Neoplasia
Preliminary data showed that Nelfinavir has selective apoptotic effects on HPV+ cervical tumor cell lines. Furthermore, in a Phase I clinical trial, the combination of NFV and chemoradiotherapy showed acceptable toxicity and…
- Trial name
- NCT01925378
- Testing
- Nelfinavir
- Where
- United States
- Sponsor
- The University of Texas Health Science Center, Houston
Cervical Cancer, Genital Warts
Cervical Intraepithelial Neoplasm (CIN) in Women (Gardasil) (V501-015)
The primary purpose of the study is to determine if GARDASIL™ (V501) is able to prevent cervical cancer.
- Trial name
- FUTURE II (NCT00092534)
- Testing
- Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine
- Volunteers
- 12,167 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
CIN2/3 Recurrence
Prognostic Value of Human Papillomavirus (HPV) Detection in Cervical Intra-epithelial Neoplasia (CIN) Recurrence After Conization
CIN2/3 have been increased for many years and mainly concern women aged 25-29 years. They are subsequent to a persistent HPV infection and are classically treated by conization.
- Trial name
- SUIVICOL (NCT01543048)
- Testing
- Study Follow-Up
- Where
- 4 sites in France
- Volunteers
- 106 people
- Sponsor
- University Hospital, Bordeaux